Why randomized controlled clinical trials do not depict accurately long- term outcomes in rheumatoid arthritis: Some explanations and suggestions for future studies

Clinical and Experimental Rheumatology

Volumn 15, Issue SUPPL. 17, 1997, Pages

  Pincus, T ^a,b   Stein, C M ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Dept of Medicine and Microbiology ^*

Author keywords

Clinical trials; Randomized controlled clinical trials; Rheumatoid arthritis treatment

Indexed keywords

ACETYLSALICYLIC ACID; ARYLPROPIONIC ACID DERIVATIVE; ASCRIPTIN; CHOLINE MAGNESIUM TRISALICYLATE; DICLOFENAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MECLOFENAMIC ACID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SALICYLIC ACID DERIVATIVE; SALSALATE; SULINDAC;

ACCURACY; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FUTUROLOGY; HUMAN; HUMAN TISSUE; LONG TERM CARE; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 0030874291     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. FRIEDMAN LM, FURBERG CD, DEMETS DL:Fundamentals of Clinical Trials. Littleton, John Wright PSG Inc., 1984; 1-225.
2. DANIELS M, HILL AB: Chemotherapy of pulmonary tuberculosis in young adults: an analysis of the combined results of three medical research council trials.Br Med J 1952; 1: 1162-8.
3. FEINSTEIN AR: An additional basic science for clinical medicine: II. The limitations of randomized trials Ann Intern Med 1983; 99: 544-50.
4. FREIMAN JA, CHALMERS TC, SMITH H J r, KUEBLER RR: The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial: survey of 71 "negative" trials. N Engl J Med 1978; 299: 69-4.
5. SACKETT DL, GENT M: Controversy in counting and attributing events in clinical trials. N Engl J Med 1979; 301: 1410-12.
6. SACKETT DL: The competing objectives of randomized trials. N Engl J Med 1980; 303: 1059-60.
7. HUSKISSON EC: Important factors in the success and failure of clinical trials (Closing Remarks).Agents Actions 1980; 7 (Suppl.): 323-4.
8. FREIREICH EJ: The randomized clinical trial as an obstacle to clinical research. In: VARCO RL, DELANEY JP (Eds.): Controversy in Surgery. 2nd edition. Philadelphia, W.B. Saunders, 1983; 5-12.
9. DIAMOND GA, FORRESTER JS: Clinical trials and statistical verdicts: probable grounds for appeal.Ann Intern Med 1983: 98: 385-94.
10. CHALMERS TC, CELANO P, SACKS HS, SMITH H JR: Bias in treatment assignment in controlled clinical trials.N Engl J Med 1983; 309: 1358-61.
11. BOMBARDIER C, TUGWELL P: Controversies in the analysis of longterm clinical trials of slow acting drugs (editorial). J Rheumatol 1985; 12: 4035.
12. GUYATT G, SACKETT D, TAYLOR DW, CHONG J, ROBERTS R, PUGSLEY S: Determining optimal therapy - randomized trials in individual patients. N Engl J Med 1986; 314: 889-92.
13. HAWLEY DJ, WOLFE F: Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies. J Rheumatol 1991; 18: 1008-14.
14. KOZMA CM, REEDER CE, LINGLE EW: Expanding Medicaid drug formulary coverage: effects on utilization of related services. Med Care 1990; 28: 963-77.
15. FERRI S, DI FEBO G, BIASCO G, CERONI G, MARIOTTI S, MURACCINI F, URBANI D: Our experience with the effectiveness and tolerance of ibuproxam in rheumatology .Minerva Med 1983; 74: 331-6.
16. GOTZSCHE PC: Methodology and overt and hidden bias in reports of 196 double blind trials of nonsteroidal anti-inflammatory drugs in rheumatoid arthritis.Controlled Clin Trials 1989; 10: 31-56.
17. KLIPPEL JH: Comment: Winning the battle, losing the war? Another editorial about RA. J Rheumatol 1990; 17: 1118-22.
18. FELSON DT, ANDERSON JJ, MEENAN RF: Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials. Arthritis Rheum 1990; 33: 140-9.
19. ROTHWELL PM: Can overall results of clinical trials be applied to all patients ? Lancet 1995; 345: 1616-19.
20. FLEMING TR, DEMETS DL: Surrogate end points in clinical trials: are we being misled ? Ann Intern Med 1996; 125: 605-13.
21. PINCUS T: Rheumatoid arthritis: disappointing long term outcomes despite successful short term clinical trials. (Editorial). J Clin Epidemiol 1988; 41: 1037-41.
22. PINCUS T, WOLFE F: Treatment of rheumatoid arthritis: challenges to traditional paradigms. Ann Intern Med 1991; 115: 825-7.
23. PINCUS T: The paradox of effective therapies but poor long term outcomes in rheumatoid arthritis Semin Arthritis Rheum 1992; 21: 2-15.
24. PINCUS T: Limitations of randomized controlled clinical trials to recognize possible advantages of combination therapies in rheumatic diseases. Semin Arthritis Rheum 1993; (Suppl. 1) 23: 2-10.
25. PINCUS T, STEIN M: What is the best source of useful data on the treatment of rheumatoid arthritis: clinical trials, clinical observations, or clinical protocols? J Rheumatol 22:1611 1617, 1995
26. PAULUS HE, FURST DE, DROMGOOLE SH: Drugs for Rheumatic Disease. New York, Churchill Livingstone, 1987; 203-26.
27. FELSON DT, ANDERSON JJ, MEENAN RF: The comparative effficacy and toxicity of second line drugs in rheumatoid arthritis: results of two meta-analyses.Arthritis Rheum 1990; 33: 1449-61.
28. WILLIAMS HJ, WARD JR, READING JC et al.: Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992; 35: 259-69.
29. PINCUS T, CALLAHAN LF, SALE WG, BROOKS AL, PAYNE LE, VAUGHN WK: Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864-72.
30. PINCUS T, CALLAHAN LF, VAUGHN WK: Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis. J Rheumatol 1987; 14: 240-51.
31. WOLFE F, HAWLEY DJ: Remission in rheumatoid arthritis. J Rheumatol 1985; 12: 245-52.
32. SHERRER YS, BLOCH DA, MITCHELL DM, ROTH SH, WOLFE F, FRIES JF: Disability in rheumatoid arthritis: comparison of prognostic factors across three populations J Rheumatol 1987; 14: 705-9.
33. WOLFE F, MITCHELL DM, SIBLEY JT et al: The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-94.
34. SCOTT DL, COULTON BL, CHAPMAN JH, BACON PA, POPERT AJ: The long term effects of treating rheumatoid arthritis. J R Coll Physicians Lond 1983; 17: 79-85.
35. RASKER JJ, COSH JA: The natural history of rheumatoid arthritis: a fifteen year follow up study. The prognostic significance of features noted in the first year.Clin Rheumatol 1984; 3: 11-20.
36. LAAKSO M, ISOMAKI HA, MUTRU O, KOOTA K: Death certificate and mortality in rheumatoid arthritis. Scand J Rheumatol 1986; 15: 129-33.
37. PINCUS T: Is mortality increased in rheumatoid arthritis ? J Musculoskel Med 1988; 5: 27-46.
38. PINCUS T, MARCUM SB, CALLAHAN LF et al:. Long term drug therapy for rheumatoid arthritis in seven rheumatology private practices: I. Nonsteroidal anti-inflammatory drugs J Rheumatol 1992; 19: 1874-84.
39. PINCUS T, MARCUM SB, CALLAHAN LF: Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second-line drugs and prednisone J Rheumatol 1992; 19: 1885-94.
40. WOLFE F, HAWLEY DJ, CATHEY MA: Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 994-1002.
41. SANY J, ANAYA JM, LUSSIEZ V, COURET M, COMBE B, DAURES JP: Treatment of rheumatoid arthritis with metho-trexate: a prospective open longterm study of 191 cases.J Rheumatol 1991; 18: 1323-7.
42. TUGWELL P, PINCUS T, YOCUM D et al.: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333: 137-41.
43. AUSTIN HA,III, KLIPPEL JH, BALOW JE, LE RICHE NGH, STEINBERG AD, PLOTZ PH, DECKER JL: Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-9.
44. PINCUS T, CALLAHAN LF: Prognostic markers of activity and damage in rheumatoid arthritis: Why clinical trials and inception cohort studies indicate more favorable outcomes than studies of patients with established disease.Br J Rheumatol 1995; 34: 196-9.
45. FUCHS HA, CALLAHAN LF, KAYE JJ, BROOKS RH, NANCE EP, PINCUS T: Radiographic and joint count findings of the hand in rheumatoid arthritis: related and unrelated findings. Arthritis Rheum 1988; 31: 44-51.
46. HAWLEY DJ, WOLFE F: Sensitivity to change of the Health Assessment Questionnaire (HAQ) and other clinical and health status measures in rheumatoid arthritis: results of short term clinical trials and observational studies versus long term observational studies.Anthritis Care Res 1992; 5: 130-6.
47. PINCUS T: Assessment of long term outcomes of rheumatoid arthritis. Rheum Dis Clin North Am 1995; 21: 619-54.
48. PAULUS HE, EGGER MJ, WARD JR, WILLIAMS HJ, and the COOPERATIVE SYSTEMATIC STUDIES OF RHEUMATIC DISEASES GROUP: Analysis of improvement in individual rheumatoid arthritis patients treated with disease modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990; 33: 477-84.
49. FELSON DT, ANDERSON J: Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: results of a pooled analysis N Engl J Med 1984; 311: 1528-33.
50. STEIN CM, WOOD AJJ, PINCUS T: Implementation of multiple outpatient formularies: Undesirable effects.Clin Pharmacol Ther 1991; 61: 1-7.
51. ADER R: The placebo effect as a conditioned response.In: ADER R, WEINER H, BAUM A: Experimental Foundations of Behavioral Medicine: Conditioning Approaches Hillsdale, NJ, Erlbaum, 1988; 47-66.
52. SPIRO HM: Doctors, Patients, and Placebos New Haven, Yale University Press, 1986.
53. EPSTEIN WV: Commentary: Expectation bias in rheumatoid arthritis clinical trials: the anti-CD4 monoclonal antibody experience. Arthritis Rheum 1996; 39: 1773-80.
54. YELIN E, CALLAHAN LF: The economic cost and social and psychological impact of musculoskeletal conditions.Arthritis Rheum 1995; 38: 1351-62.
55. MEENAN RF, PINCUS T: The status of patient status measures. J Rheumatol 1987; 14: 411-4.
56. PINCUS T: Why should rheumatologists collect patient self report questionnaires in routine rheumatologic care ?Rheum Dis Clin North Am 1995; 21: 271-317.
57. PINCUS T, WOLFE F, CALLAHAN LF: Updating a reassessment of traditional paradigms concerning rheumatoid arthritis In: WOLFE F, PINCUS T (Eds.): Rheumatoid Arthritis: Pathogenesis, Assessment, Outcome, and Treatment New York, Marcel Dekker, Inc., 1994; 1-74
58. WOLFE F, PINCUS T: Data collection in the clinic. Rheum Dis Clin North Am 1995; 21: 321-58.
59. PINCUS T: Documenting quality management in rheumatic disease: Are patient questionnaires the best (and only) method? Arthritis Care Res 1996; 9: 339-48.